Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
StrykerLTS:0R2S +0.41%93 Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus rates LTS:0R2S with a GF Score™ of 93/100 and a GF Value™ of $410.99 (Modestly Undervalued). The stock has 1 warning sign investors should review. Among 347 Medical Devices & Instruments companies, Stryker ranks worse than 288184.15% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Stryker's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0R2S vs MDT, ABT, BSX: Buyback Yield % Comparison
For the Medical Devices subindustry, Stryker's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stryker Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stryker's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Stryker's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stryker (LTS:0R2S) has a Buyback Yield % of 0.00 as of Jul. 16, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stryker and its competitors. Over the past decade, Stryker's Buyback Yield % has ranged from 0.03 to 1.45. According to the industry distribution chart, Stryker ranks #999999 out of 347 companies in the Medical Devices & Instruments industry.
Is Stryker's Buyback Yield % too high?
Stryker's current Buyback Yield % is 0.00. Over the past 10 years, this metric has ranged from a low of 0.03 to a high of 1.45. Based on the distribution chart, Stryker ranks #999999 out of 347 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Stryker has a GF Score™ of 93/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stryker's Buyback Yield % compare to MDT and ABT?
According to the Medical Devices & Instruments industry distribution chart, Stryker ranks #999999 out of 347 companies for Buyback Yield %. This places Stryker in the lower half of its industry. Historically, Stryker's own Buyback Yield % has ranged from 0.03 to 1.45 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Stryker and its competitors. Stryker's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stryker stock overvalued right now?
Based on GuruFocus' analysis, Stryker (LTS:0R2S) is currently considered Modestly Undervalued. The stock's GF Value™ is $410.99, compared to a current price of $314.66 — trading 23.4% below its estimated fair value. The current Buyback Yield % is 0.00. Stryker's overall GF Score™ is 93/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Stryker (LTS:0R2S), the current Buyback Yield % is 0.00 as of Jul. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stryker (LTS:0R2S) Overvalued in 2026?
Based on GuruFocus' analysis, Stryker stock appears to be undervalued.
The current stock price of $314.66 is trading 23.4% below its estimated GF Value™ of $410.99.
GuruFocus considers Stryker to be Modestly Undervalued.
Key valuation signals for LTS:0R2S:
Buyback Yield %: 0.00
GF Value™: $410.99 vs. price of $314.66 (23.4% below fair value)
No single metric tells the full story. See the LTS:0R2S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Roughly one-fourth of Stryker's total revenue currently comes from outside the United States.
93GF Score
Get the complete analysis for LTS:0R2S
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0R2S has been successfully added to your 
